Radeas admitted that between January 2016 and September 2021, it billed Medicare for two kinds of drug testing, which are usually performed on the same specimen separately and at different times to obtain presumptive and confirmatory results. Radeas performed both kinds of testing at about the same time and submitted the results to healthcare providers simultaneously, without consulting with a physician about the need for the second, more expensive test, the Justice Department said.
Radeas, based in Wake Forest, N.C., also admitted that between May 2013 and April 2021, it paid sales organizations based on how many drug testing referrals their representatives made to Radeas, the Justice Department said.
In addition to the settlement sum, Radeas entered into a five-year corporate integrity agreement with the Office of the Inspector General for HHS. The agreement includes yearly Anti-Kickback Statute compliance reviews and yearly reviews of Radeas’ claims to federal healthcare programs, the Justice Department said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.